Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer
PITTSBURGH , July 18, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products
View HTML
Toggle Summary Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment
MINNEAPOLIS, Minn ., June 26, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement
View HTML
Toggle Summary Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Officer of Helomics
MINNEAPOLIS , June 12, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Amelia Warner , Pharm.D., RPh, as the
View HTML
Toggle Summary Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc.
Nasdaq ticker expected to change to POAI Effective Thursday, June 13, 2019 MINNEAPOLIS , June 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery,
View HTML
Toggle Summary Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant
MINNEAPOLIS , May 21, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. , (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that its Helomics division has been selected as the
View HTML
Toggle Summary Precision Therapeutics Gains Extension for Nasdaq Compliance
MINNEAPOLIS , May 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that Nasdaq has determined that the Company is eligible for a
View HTML
Toggle Summary Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Management to Host Conference Call to Review Financial Results and Provide Corporate Update at 4:30PM Today MINNEAPOLIS , May 15, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized
View HTML
Toggle Summary Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019
Conference Call to be held May 15, 2019 , at 4:30pm Eastern Time MINNEAPOLIS , May 13, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces that it will report First Quarter 2019 financial results for the period ended March 31, 2019 ,
View HTML
Toggle Summary Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next-Generation Patient Registry for Alopecia Areata Research
MINNEAPOLIS and SAN RAFAEL, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a services agreement between its wholly owned subsidiary, Helomics and the National Alopecia Areata Foundation (NAAF), which serves the
View HTML
Toggle Summary Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments
Collaboration Receives $300,000 CAD Grant to Further Develop and Commercialize TumorGenesis Oncology Discovery Technologies MINNEAPOLIS , April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary,
View HTML